NTRK1 and clear cell renal carcinoma: Sunitinib, a broad-spectrum small-molecule inhibitor of receptor tyrosine kinases (RTKs), is currently the standard treatment for first-line treatment of advanced clear cell renal cell carcinoma (ccRCC).